Semaglutide, the active ingredient in Ozempic and Wegovy, was patented a decade earlier than tirzepatide, leading to an earlier expiration of its core patents. Semaglutide's patents in China are set to expire in 2026, with some secondary patents extending into the early 2030s
Administer 5-Amino-1MQ concurrently or add NAD+ precursors like NMN (nicotinamide mononucleotide) at 250500 mg/kg daily
Reference: Holst JJ (2007)
Hydrogen sulfide producers drive a Diarrhea-Like phenotype and a methane producer drives a Constipation-Like phenotype in animal models
Medications know to cause bone marrow suppression (e.g., myelosuppressive antineoplastic agents) may result in a blunted or impeded response to methylcobalamin, vitamin B12 therapy
Symptoms include hyperthermia, muscle rigidity, autonomic instability, and altered mental status